Aptahem enters into production agreement with BioSpring
Aptahem AB (publ) can announce today that it has entered into a production agreement with BioSpring, a world-leading producer of oligonucleotides. BioSpring has been contracted to manufacture the substance in drug candidate Apta-1 for the company’s preclinical and upcoming clinical developmental work.
Aptahem AB (publ) can announce today that it has entered into a production agreement with a world-leading producer of oligonucleotides. BioSpring has been active since 1997, and in 2007 it acquired the cGMP certification (current Good Manufacturing Practice) for manufacturing therapeutic oligonucleotides. BioSpring has been contracted for the manufacturing of the substances in the aptamer-based drug candidate Apta-1. The agreement with BioSpring is the last step towards the completion of Aptahem’s new development plan for Apta-1, which will be released shortly.
CEO of Aptahem Mikael Lindstam comments, “It is with great joy that we can announce today this agreement that will take us one step closer to a clinical trial of Apta-1. BioSpring are world-leading experts on the production of aptamer-based products and they will be a great resource for us for the execution of our development plan. Thanks to the promising results of the preclinical animal models and this competent substance manufacturer, we are now well equipped for the upcoming clinical work.”
Based in Frankfurt, BioSpring possesses cGMP certification and is a well-known actor providing the global market with synthetic oligonucleotides for therapeutic, diagnostic and research-related purposes. The company has broad competence in manufacturing and it offers small scale production for research to full-scale commercial production of approved drugs. BioSpring also offers numerous technical services that will support Aptahem’s developmental work.
For further information:
Mikael Lindstam, CEO, Aptahem AB
Tel: + 46 (0)766-33 36 99
This information is information which Aptahem AB (publ) is obliged to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person, for publication on 10 August 2017.
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.